Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2017 1
2018 3
2019 4
2020 12
2021 12
2022 14
2023 15
2024 6
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, Viteri S, Han JY, Kim SW, Lee CK, Sabari JK, Spira AI, Yang TY, Kim DW, Lee KH, Sanborn RE, Trigo J, Goto K, Lee JS, Yang JC, Govindan R, Bauml JM, Garrido P, Krebs MG, Reckamp KL, Xie J, Curtin JC, Haddish-Berhane N, Roshak A, Millington D, Lorenzini P, Thayu M, Knoblauch RE, Cho BC. Park K, et al. J Clin Oncol. 2021 Oct 20;39(30):3391-3402. doi: 10.1200/JCO.21.00662. Epub 2021 Aug 2. J Clin Oncol. 2021. PMID: 34339292 Free PMC article. Clinical Trial.
METHODS: CHRYSALIS is a phase I, open-label, dose-escalation, and dose-expansion study, which included a population with EGFR Exon20ins NSCLC. The primary end points were dose-limiting toxicity and overall response rate. We report findings from the postplatinum EGFR Exon20 …
METHODS: CHRYSALIS is a phase I, open-label, dose-escalation, and dose-expansion study, which included a population with EGFR Exon20ins NSCL …
Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group.
Chevalley T, Brandi ML, Cashman KD, Cavalier E, Harvey NC, Maggi S, Cooper C, Al-Daghri N, Bock O, Bruyère O, Rosa MM, Cortet B, Cruz-Jentoft AJ, Cherubini A, Dawson-Hughes B, Fielding R, Fuggle N, Halbout P, Kanis JA, Kaufman JM, Lamy O, Laslop A, Yerro MCP, Radermecker R, Thiyagarajan JA, Thomas T, Veronese N, de Wit M, Reginster JY, Rizzoli R. Chevalley T, et al. Aging Clin Exp Res. 2022 Nov;34(11):2603-2623. doi: 10.1007/s40520-022-02279-6. Epub 2022 Oct 26. Aging Clin Exp Res. 2022. PMID: 36287325 Free PMC article. Review.
Skin photosynthesis is the main source of vitamin D. Limited sun exposure and insufficient dietary vitamin D supply justify vitamin D supplementation in certain age groups. ...
Skin photosynthesis is the main source of vitamin D. Limited sun exposure and insufficient dietary vitamin D supply justify vitamin D …
Alternative and complementary therapies in osteoarthritis and cartilage repair.
Fuggle NR, Cooper C, Oreffo ROC, Price AJ, Kaux JF, Maheu E, Cutolo M, Honvo G, Conaghan PG, Berenbaum F, Branco J, Brandi ML, Cortet B, Veronese N, Kurth AA, Matijevic R, Roth R, Pelletier JP, Martel-Pelletier J, Vlaskovska M, Thomas T, Lems WF, Al-Daghri N, Bruyère O, Rizzoli R, Kanis JA, Reginster JY. Fuggle NR, et al. Aging Clin Exp Res. 2020 Apr;32(4):547-560. doi: 10.1007/s40520-020-01515-1. Epub 2020 Mar 13. Aging Clin Exp Res. 2020. PMID: 32170710 Free PMC article. Review.
These alternative therapies may have a limited evidence base and, for this reason, are often only afforded brief reference (or completely excluded) from current OA guidelines. ...Matrix-assisted ACI has demonstrated exceedingly limited, symptomatic improvements in t …
These alternative therapies may have a limited evidence base and, for this reason, are often only afforded brief reference (or comple …
Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes.
Leslie RD, Ma RCW, Franks PW, Nadeau KJ, Pearson ER, Redondo MJ. Leslie RD, et al. Lancet Diabetes Endocrinol. 2023 Nov;11(11):848-860. doi: 10.1016/S2213-8587(23)00159-6. Epub 2023 Oct 4. Lancet Diabetes Endocrinol. 2023. PMID: 37804855 Review.
Although pragmatically helpful, disease classification can become complex and limit advances in research and medical care. Here, we describe diabetes heterogeneity, highlighting recent approaches that could facilitate management by integrating three disease models across a …
Although pragmatically helpful, disease classification can become complex and limit advances in research and medical care. Here, we d …
Transcranial magnetic stimulation of the brain: What is stimulated? - A consensus and critical position paper.
Siebner HR, Funke K, Aberra AS, Antal A, Bestmann S, Chen R, Classen J, Davare M, Di Lazzaro V, Fox PT, Hallett M, Karabanov AN, Kesselheim J, Beck MM, Koch G, Liebetanz D, Meunier S, Miniussi C, Paulus W, Peterchev AV, Popa T, Ridding MC, Thielscher A, Ziemann U, Rothwell JC, Ugawa Y. Siebner HR, et al. Clin Neurophysiol. 2022 Aug;140:59-97. doi: 10.1016/j.clinph.2022.04.022. Epub 2022 May 18. Clin Neurophysiol. 2022. PMID: 35738037 Free PMC article. Review.
An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis.
Schini M, Johansson H, Harvey NC, Lorentzon M, Kanis JA, McCloskey EV. Schini M, et al. J Endocrinol Invest. 2024 Mar;47(3):501-511. doi: 10.1007/s40618-023-02219-9. Epub 2023 Oct 24. J Endocrinol Invest. 2024. PMID: 37874461 Free PMC article. Review.
We also present arguments as to why screening with FRAX should be considered. FRAX has several limitations which are described in this review. This review coincides with the release of a version, FRAXplus, which addresses some of these limitations....
We also present arguments as to why screening with FRAX should be considered. FRAX has several limitations which are described in thi …
Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?
Rozenberg S, Al-Daghri N, Aubertin-Leheudre M, Brandi ML, Cano A, Collins P, Cooper C, Genazzani AR, Hillard T, Kanis JA, Kaufman JM, Lambrinoudaki I, Laslop A, McCloskey E, Palacios S, Prieto-Alhambra D, Reginster JY, Rizzoli R, Rosano G, Trémollieres F, Harvey NC. Rozenberg S, et al. Osteoporos Int. 2020 Dec;31(12):2271-2286. doi: 10.1007/s00198-020-05497-8. Epub 2020 Jul 8. Osteoporos Int. 2020. PMID: 32642851 Free PMC article. Review.
Despite controversy over associated side effects, which has limited its use in recent decades, the potential role for MHT soon after menopause in the management of postmenopausal osteoporosis is increasingly recognized. ...Current literature suggests robust anti-fracture e …
Despite controversy over associated side effects, which has limited its use in recent decades, the potential role for MHT soon after …
Recent sarcopenia definitions-prevalence, agreement and mortality associations among men: Findings from population-based cohorts.
Westbury LD, Beaudart C, Bruyère O, Cauley JA, Cawthon P, Cruz-Jentoft AJ, Curtis EM, Ensrud K, Fielding RA, Johansson H, Kanis JA, Karlsson MK, Lane NE, Lengelé L, Lorentzon M, McCloskey E, Mellström D, Newman AB, Ohlsson C, Orwoll E, Reginster JY, Ribom E, Rosengren BE, Schousboe JT, Shiroma EJ, Harvey NC, Dennison EM, Cooper C; International Musculoskeletal Ageing Network. Westbury LD, et al. J Cachexia Sarcopenia Muscle. 2023 Feb;14(1):565-575. doi: 10.1002/jcsm.13160. Epub 2023 Jan 5. J Cachexia Sarcopenia Muscle. 2023. PMID: 36604970 Free PMC article.
However, comparisons of the performance of these approaches in terms of thresholds employed, concordance in individuals and prediction of important health-related outcomes such as death are limited. We addressed this in a large multinational assembly of cohort studies that …
However, comparisons of the performance of these approaches in terms of thresholds employed, concordance in individuals and prediction of im …
Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension.
Schutte AE, Jafar TH, Poulter NR, Damasceno A, Khan NA, Nilsson PM, Alsaid J, Neupane D, Kario K, Beheiry H, Brouwers S, Burger D, Charchar FJ, Cho MC, Guzik TJ, Haji Al-Saedi GF, Ishaq M, Itoh H, Jones ESW, Khan T, Kokubo Y, Kotruchin P, Muxfeldt E, Odili A, Patil M, Ralapanawa U, Romero CA, Schlaich MP, Shehab A, Mooi CS, Steckelings UM, Stergiou G, Touyz RM, Unger T, Wainford RD, Wang JG, Williams B, Wynne BM, Tomaszewski M. Schutte AE, et al. Cardiovasc Res. 2023 Mar 31;119(2):381-409. doi: 10.1093/cvr/cvac130. Cardiovasc Res. 2023. PMID: 36219457 Free PMC article.
Additional unique challenges in specific regions include conflict, wars, migration, unemployment, rapid urbanization, extremely limited funding, pollution, COVID-19-related restrictions and inequalities, obesity, and excessive salt and alcohol intake. ...
Additional unique challenges in specific regions include conflict, wars, migration, unemployment, rapid urbanization, extremely limited …
63 results